FDA Approves Symbicort For Treatment of Asthma in Pediatric Patients
In major news for pediatric asthma patients, AstraZeneca this week announced that the U.S. Food and Drug Administration (FDA) approved SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol 80/4.5 micrograms for the treatment of asthma in pediatric patients ages 6–12.
SYMBICORT 80/4.5 and 160/4.5 are already approved in the U.S. to treat asthma in patients 12 years and older. SYMBICORT 160/4.5 is also approved for the maintenance treatment of airflow obstruction in Chronic Obstructive Pulmonary Disease (COPD) in adults.
“SYMBICORT is a cornerstone product in our growing respiratory franchise and we are pleased to now be able to offer this medicine to younger patients, helping to control and prevent asthma symptoms,” Gregory Keenan, vice president, Medical Affairs and U.S. head medical officer said.
This news comes as a particularly brutal winter and flu season have wreaked havoc on the respiratory systems of many, especially those who already have conditions such as asthma. With the success medications such as SYMBICORT have had in the management and treatment of this condition in adult and adolescent patient populations, this approval may go a long way toward decreasing the number of sick days students need, improving school performance and participation and promoting better overall respiratory health.
As a respiratory care practitioner, what are some of the ways you treat asthma in pediatric populations? How will the availability of drugs such as SYMBICORT for younger children benefit your practice? Let us know!